Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Celebrating the success of the COVID-19 vaccines, and looking to the future

By Michael Ybarra  |    March 27, 2023
It’s been over three years since I saw my first COVID-19 patient in the emergency department. The image of that x-ray is burned into my memory: clusters of white spots spread out across both sides of...   Read More

IRA Impacts: Cancer treatment research and development

By Andrew Powaleny  |    March 23, 2023
Last month marked the one-year anniversary of the reignited Cancer Moonshot, the White House’s ambitious goal of reducing the death rate from cancer by at least 50% over the next 25 years. Much of...   Read More

Food Allergy Highlights Opportunities for Inclusive, Representative Research Studies

By Anita Roach M.S.  |    March 22, 2023
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...   Read More

PhRMA submits comments to OSTP on enhancing clinical trial diversity

By Maria Apostolaros  |    March 21, 2023
The White House’s Office of Science and Technology Policy (OSTP) recently solicited stakeholder feedback on the clinical research infrastructure for emergency clinical trials, for which PhRMA...   Read More

U.S. biopharmaceutical exports support jobs, innovation

By Brian Picone  |    March 20, 2023
The U.S. Census Bureau and the U.S. Bureau of Economic Analysis recently published annual trade data indicating that U.S. exports of goods exceeded $2 trillion in 2022. According to the report, U.S....   Read More

What we’ve learned from three years of fighting COVID-19

By Andrew Powaleny  |    March 20, 2023
Three years ago, amidst an unprecedented public health crisis, biopharmaceutical industry made a commitment to fight COVID-19. Leveraging decades of research and investments in emerging technologies...   Read More

Will the administration capitalize on the Indo-Pacific Economic Framework to drive medical innovation?

By Douglas Petersen  |    March 13, 2023
In December 2022, the United States launched negotiations for the Indo-Pacific Economic Framework (IPEF) with thirteen countries throughout the Indo-Pacific region, including Australia, India,...   Read More

Insurer and PBM tactics are shifting higher costs to patients with chronic and complex conditions

By Priscilla VanderVeer  |    March 2, 2023
Health plans are increasingly using deductibles and coinsurance to shift more of the cost of care to chronically ill patients taking brand medicines. As data from IQVIA show, this alarming trend is...   Read More

Why Congress should prioritize fixing the 340B program

By Nicole Longo  |    March 2, 2023
Nearly all Americans nationwide agree: Lowering out-of-pocket costs for health care should be a top priority for policymakers. Luckily, there are commonsense policies Congress could implement to...   Read More

FDA-USPTO collaboration initiatives should be evidence-based, prioritize innovation

By Megan Van Etten  |    March 1, 2023
The United States Patent and Trademark Office (USPTO) and the U.S. Food and Drug Administration (FDA) are in the process of considering new collaboration initiatives aimed at biopharmaceutical...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates